Provectus Biopharmaceuticals: 10% owner Pershing Edward exercised 22,609 shares

What happened

• Pershing Edward, a 10% owner, exercised or converted derivatives to acquire 22,609 shares on Oct 10, 2026. The filing reports an acquisition of 22,609 derivative shares at $0.00 per share, total $0.
• The filing also shows a separate derivative disposition entry listed as N/A shares at $0.00.

Key details

• Transaction date: Oct 10, 2026; price: $0.00 per share; total reported value: $0.
• Form filed on Oct 13, 2026.
• Shares owned after the transaction: not stated in the filing.
• Relevant footnotes from the filing:
  • F1: Each share of Series D-1 preferred is convertible into 10 shares of common stock.
  • F2: Series D-1 preferred automatically converts into common stock on Dec 31, 2028, unless earlier converted under the certificate of designation.
  • F3: The reporting person could have elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note issued in the 2025 financing at $2.862 per share; that note converted automatically after twelve months if not earlier converted.
  • F4: On Oct 10, 2026, the 2025 note converted into 22,609 shares of Series D-1 preferred stock.
• The filing does not indicate that it was filed late.

Why it may matter

• The transaction reported is an exercise/conversion of a derivative into preferred shares; no market sale of common stock is reported in this filing.
• Pershing Edward is reported as a 10% owner, indicating a large holder rather than an executive.
• A filing does not show why the insider traded or why the company acted.